Intermittent intravenous cyclophosphamide pulse therapy for the treatment of active interstitial lung disease associated with collagen vascular diseases

References

• Schnabel A, Reuter M, Gross WL. Intravenous pulse cyclophos-phamide in the treatment of interstitial lung disease due to colla-gen vascular diseases. Arthritis Rheum 1998;41:1215–20.
   Google Scholar
• Kocheril SV, Appleton BE, Somers EC, Kazerooni EA, Flaherty KR, Martinez FJ, et al. Comparison of disease progression and mortality of connective tissue disease-related interstitial lung disease and idiopathic interstitial pneumonia. Arthritis Rheum. 2005;53:549–57.
   PubMed Web of Science ®Google Scholar
• Hunninghake GW, Kalica AR. Approaches to the treatment of pulmonary fibrosis. Am J Respir Crit Care Med 1995;151:915–8.
   PubMed Web of Science ®Google Scholar
• Steen VD, Lanz JK, Jr., Conte C, Owens GR, Medsger TA, Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994;37:1290–6.
   Google Scholar
• Johnson MA, Kwan S, Snell NJ, Nunn AJ, Darbyshire JH, Turner-Warwick M. Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989;44: 280–8.
   Google Scholar
• Eiser AR, Shanies HM. Treatment of lupus interstitial lung disease with intravenous cyclophosphamide. Arthritis Rheum 1994;37: 428–31.
   PubMedGoogle Scholar
• Shinohara T, Hidaka T, Matsuki Y, Ishizuka T, Takamizawa M, Kawakami M, et al. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclo-phosphamide pulse therapy. Intern Med 1997;36:519–23.
   PubMedGoogle Scholar
• Kohno N, Kyoizumi S, Awaya Y, Fukuhara H, Yamakido M, Aki-yama M. New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6. Chest 1989;96: 68–73.
   Google Scholar
• Kohno N. Serum marker KL-6/MUC1 for the diagnosis and man-agement of interstitial pneumonitis. J Med Invest 1999;46:151–8.
   PubMedGoogle Scholar
• American Thoracic Society; European Respiratory Society. Amer-ican Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Inter-stitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165: 277–304.
   Google Scholar
• Fukuda T, Setoguchi M, Inaba K, Shoji H, Tahara T. The anti-emetic profile of Y-25130, a new selective 5-HT3 receptor antago-nist. Eur J Pharmacol 1991;196: 299–305.
   Google Scholar
• Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–9.
   PubMed Web of Science ®Google Scholar
• McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of in-travenous cyclophosphamide in severe systemic lupus erythemato-sus. N Engl J Med 1988;318:1423–31.
   PubMed Web of Science ®Google Scholar
• Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945–50.
   PubMed Web of Science ®Google Scholar
• Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treat-ment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990;89:403–10.
   Google Scholar
• Haubitz M, Schellong S, Gobel U, Schurek HJ, Schaumann D, Koch KM, Brunkhorst R. Intravenous pulse administration of cy-clophosphamide versus daily oral treatment in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998;41:1835–44.
   Google Scholar
• Giacomelli R, Valentini G, Salsano F, Cipriani P, Sambo P, Con-forti ML, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Ftheumatol 2002;29:731–6.
   Google Scholar
• Pakas I, Ioannidis JP, Malagari K, Skopouli FN, Moutsopoulos HM, Vlachoyiannopoulos PG. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Ftheumatol 2002;29:298–304.
   Google Scholar
• Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32: 1128–34.
   Google Scholar
• Gruhn WB, Diaz-Buxo JA. Cyclosporine treatment of steroid re-sistant interstitial pneumonitis associated with dermatomyositis/ polymyositis. J Ftheumatol 1987;14:1045–7.
   Google Scholar
• Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Ftheumatol 1999;26:1527–33.
   Google Scholar
• Okada M, Suzuki K, Nakanishi T, Nakashima M. The serum levels of KL-6 are positively correlated with those of CA15-3 in patients with interstitial pneumonia associated with collagen diseases. Res-pirology 2006;11:509–10.
   Google Scholar
• Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progres-sive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;158:1680–4.
   PubMed Web of Science ®Google Scholar
• Yokoyama A, Kondo K, Nakajima M, Matsushima T, Takahashi T, Nishimura M, et al. Prognostic value of circulating KL-6 in idiopathic pulmonary fibrosis. Respirology 2006;11:217–20.
   PubMedGoogle Scholar
• Bandoh S, Fujita J, Ohtsuki Y, Ueda Y, Hojo S, Tokuda M, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000;59:257–62.
   PubMed Web of Science ®Google Scholar